stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

ProQR Therapeutics N.V.

Netherlands · NASDAQ: PRQR · Market cap: · P/E: · P/S:

ProQR is a biotech company that designs RNA-based medicines to treat rare genetic diseases that currently have few or no treatment options.

ProQR is a small biotech company with one big idea: use RNA, the messenger molecule that carries instructions from DNA to the cell's protein-making machinery, as the raw material for drugs. Many rare genetic diseases happen because a single tiny error in a gene produces a broken or missing protein. ProQR's approach is to step in at the RNA stage and either patch over the error or change how the message is read, so the body can make a working protein again. Its main technology, which it calls Axiomer, is an RNA editing platform that can be aimed at specific spots in RNA to correct disease-causing mistakes.

ProQR Therapeutics (PRQR) Axiomer RNA editing platform: line art illustration of A stylized RNA strand with a small editing molecule docking onto a single letter
Axiomer RNA editing
Axiomer aims to edit RNA messages rather than the DNA code itself.

The company is based in Leiden, the Netherlands, a city with a long biotech tradition, and it trades on Nasdaq. Its pipeline focuses on severe genetic disorders in the liver, central nervous system, and eye — areas where a single genetic defect causes serious harm and where patients often have no good options. Because these are rare diseases, ProQR can pursue regulatory pathways that allow smaller, faster clinical trials, and it can potentially charge premium prices for a treatment that changes the course of a disease rather than just easing symptoms. The hard truth about this business is that drug development is slow, expensive, and very risky. ProQR has had pipeline setbacks — a few years ago it discontinued a closely watched inherited blindness program after it failed a key trial, a painful moment for a small company that had invested years in it. The company has no approved products on the market today, so it does not yet earn revenue from selling medicine. Instead, it funds its research through a mix of cash on hand, partnerships, and raising money from investors. That means it burns through cash each year and depends on convincing investors — or partners like larger pharma companies — that its RNA editing science will eventually produce a drug that works.


What makes ProQR interesting is the bet it is making on RNA editing as a whole new category of medicine. If the platform works, it could become a kind of programmable fix for a long list of genetic diseases, not just one. Partners and investors pay attention because that kind of platform, if proven, is far more valuable than a single drug. But the flip side is that the science is still early, trials are uncertain, and the company is small enough that a single failure or a funding crunch could hurt badly. For a patient with a rare genetic disease, though, ProQR represents something precious: a company trying to build a treatment where almost nobody else is looking.

Saved answer · last researched 16 Nov 2026